Fortunately, yes. In short:Tom gave rundown of company/trial...

Fortunately, yes.

In short:

1. Tom gave rundown of company/trial history.
2. Recent third-party analysis by Clarivate determined impact stemming from new weight loss drugs (Ozempic, Wegovy etc) to future revenue/potential market for Invex was very high.
3. Board decided to finalise Phase III trial to protect capital and minimise expenses.
4. Focus now appears to be on TBI and other potential similar use cases (meningitis, hydrocephalus etc).
5. Other “strategic options” all on the table (including handing cash back to shareholders, should that be deemed a suitable path by the Board).
6. Rep from Candour Advisory was the only caller to ask multiple questions – primarily on upcoming expenditure, strategic options moving forward, cash burn and TBI market (addressing the fact that the TBI market is quite competitive in the bio space).
7. Final cash position to be ascertained once trial is completely finalised. Invex to inform market once they have all the necessary details.

Near term catalysts

1. Invex also expects to secure Orphan Drug Designation for Exenatide in TBI from the US FDA, also in CY2023.
2. The company continues to develop plans for a proof-of-concept Phase II clinical trial in moderate to severe TBI with Exenatide.
3. Costs regarding dosing regimens and route of administration for such a trial were said to be minimal (low cash burn).